Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

HCW Biologics Q3 2026 Results: Net Loss of $3.22M, Loss Narrows

HCW Biologics Inc. reported a significant revenue increase to $6.7 million for the nine months ended September 30, 2026, primarily driven by a $3.5 million noncash licensing agreement. Despite this, the company recorded a net loss of $5.0 million for the period and an accumulated deficit of $113.5 million, reflecting ongoing research and development costs and substantial equity dividends to investors.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.0
Gross profit0.00.0
Profit before tax-3.2-4.6
Net income-3.2-4.6
EPS (diluted, $ a share)$-2.83$-12.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+255.4%
Gross margin50.7%
Source

10-Q filed with the SEC, NASDAQ: HCWB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

HCW Biologics Inc.: key numbers

Share price
$0.7767Close, Nov 17
Market cap
$2.44M
Shares outstanding
3.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from HCW Biologics Inc.

All →
8:32 AM ET 8-K
Financial Results

HCW Biologics Financial Results

HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.

Term
Q3 2026

“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
9:05 AM ET 8-K
Loan & Debt

HCW Biologics $10.2M Debt Financing with Streeterville Capital, LLC

HCW Biologics entered into a Notes Purchase Agreement for the issuance of two secured promissory notes totaling $10.2 million in principal ($3.2M A-1 Note and $7.0M B Note). The financing provides immediate net proceeds of approximately $3.0 million, with the remaining $7.0 million held in a restricted account to be released as the A-1 Note is repaid. Proceeds will fund the Phase 1 clinical study of HCW9302 for alopecia areata through its expected readout in Q1 2027.

Value
$10.2M
Counterparty
Streeterville Capital, LLC
Term
24 months
8:59 AM ET 8-K
Capital Raise

HCW Biologics Capital Raise of $1.5M

HCW Biologics entered into a securities purchase agreement with an institutional investor to raise approximately $1.5 million through the sale of 903,614 units. Each unit consists of a pre-funded warrant and a common stock purchase warrant, with proceeds intended for working capital and clinical development activities.

Value
$1.5M
Counterparty
institutional investor

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.